<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815620</url>
  </required_header>
  <id_info>
    <org_study_id>ZBB-NET-1</org_study_id>
    <nct_id>NCT00815620</nct_id>
  </id_info>
  <brief_title>Best Therapy for Patients With Neuroendocrine Tumors</brief_title>
  <acronym>BESTTHERAPYNET</acronym>
  <official_title>Best Therapy for Patients With Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zentralklinik Bad Berka</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zentralklinik Bad Berka</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective observational study containing three arms comprising different therapeutic
      measures to treat patients with neuroendocrine tumors in advanced stages. The therapy arms
      include local ablative therapy such as TACE or SIRT, surgery and RFA with peptide receptor
      radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      Prospective observational study comparing ablative measures as TACE or SIRT with surgery/RFA
      and with peptide receptor radio-therapy in patients with advanced well-differentiated
      neuroendocrine tumors with lymph node or distant metastases (N1, M1) Prospective evaluation
      Primary end points: time to progression Secondary end points: survival, quality of life
      (EORTC-QLQ30), weight, time of hospitalization, Karnofsky index) Non-randomized cohort study
      Number of patients needed in all groups: 70 per group, 210 overall Evaluation of response to
      therapy every 3-6 months by imaging, clinical status, weight, quality of life,
      Karnofsky-index Cross-over allowed if therapy changes
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival, quality of life (EORTC-QLQ30), weight, time of hospitalization, Karnofsky index</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>patients undergoing local ablative therapy such as transcatheter-arterial chemoembolization or selective interal radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>patients undergoing surgery or radiofrequency ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>patients undergoing peptide receptor radiotherapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with neuroendocrine tumors in a tertiary referal center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven neuroendocrine tumor (WHO class I-II, TNM grading 1-2)

          -  Advanced disease with lymph node or distant metastases (N1, M1) undergoing
             cytoreduction by surgery/local ablative therapy or peptide receptor radiotherapy

          -  curative intent of all therapies possible

        Exclusion Criteria:

          -  Undifferentiated neuroendocrine carcinoma (WHO class III, TNM grading 3)

          -  secondary tumor

          -  advanced carcinoid heart disease requiring surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter HÃ¶rsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zentralklinik Bad Berka GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2008</study_first_submitted>
  <study_first_submitted_qc>December 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2008</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zentralklinik Bad Berka</investigator_affiliation>
    <investigator_full_name>Dieter Hoersch MD</investigator_full_name>
    <investigator_title>Senior consultant</investigator_title>
  </responsible_party>
  <keyword>neuroendocrine tumors</keyword>
  <keyword>transcatheter arterial chemoembolization</keyword>
  <keyword>selective internal radiotherapy</keyword>
  <keyword>surgery</keyword>
  <keyword>radio-frequency ablation</keyword>
  <keyword>peptide-receptor radiotherapy</keyword>
  <keyword>progression-free survival</keyword>
  <keyword>quality of life</keyword>
  <keyword>overall survival</keyword>
  <keyword>weight</keyword>
  <keyword>time of hospitalization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

